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Background/objectives: There is limited information on the prognosis of stress cardiomyopathy (SCM) after
hospital discharge. The aim of this retrospective cohort study was to determine the post-discharge prognosis
of women with SCM compared to female controls with ST-segment elevation myocardial infarction (STEMI).
Methods: SCMcaseswere identiﬁed through chart reviews ofwomenhospitalized at a single tertiary caremedical
center between 2002 and 2012. Controlswere randomly selected (2:1 ratio) amongwomen admittedwith a val-
idated diagnosis of STEMI during the same period. The primary outcome was a composite of cardiovascular
readmissions and death from any cause. Risk of the composite outcome was estimated from multivariate Cox
proportional hazard regression models.
Results: Over an average follow-up of 24 months, incidence rates of the composite outcomewere 140/1000 per-
son-years among cases (n= 50) and 347/1000 person-years among controls (n= 100; P b 0.001). SCMwomen
had a lower unadjusted risk of cardiovascular readmissions and death vs. STEMI women (HR: 0.47; 95% CI: 0.27,
0.82). This difference in risk was reduced after adjustment for demographic and clinical confounders (HR: 0.64;
95% CI: 0.30, 1.33). The lower risk of developing the composite outcome among SCM women was driven by a
lower risk of death, while the risk of cardiovascular readmissions was similar between groups.
Conclusion: Risk of death and cardiovascular readmissions post-discharge was lower among women with SCM
than amongwomenwith STEMI. Incidence rates of cardiovascular readmissions, however, were similar, indicating
that SCM may not be a benign condition.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Stress cardiomyopathy (SCM) [1], also known as Takotsubo cardio-
myopathy, transient apical ballooning syndrome, or broken heart
syndrome,was ﬁrst described in the early 90s in Japan [2]. SCM, however,
is prevalent worldwide [3] and accounts for up to 3% of hospital admis-
sions for acute coronary syndromes, reaching almost 10% of all admis-
sions among female patients [4–7]. Up to 90% of cases are diagnosed in
post-menopausal women [5]. An emotionally stressful trigger such as
an accident, the death or illness of a close relative, or a natural disasterability and freedom from bias of
nd Preventive Medicine, Coro
03, United States. Tel.: +1 401
u (E. Salmoirago-Blotcher).
land Ltd. This is an open access article[8] is typically identiﬁable in 40 to 70% of patients,while a physical stress-
or is present in approximately one third [5,9]. The clinical presentation of
SCM is similar to that of an acute coronary syndrome accompanied by
signs and symptoms of heart failure. The echocardiogram typically
shows transient left ventricular systolic dysfunction and wall motion
abnormalities involving the apical and mid-portions of the left ventricle,
although atypical forms have been described [9–12].
Although this condition can present serious acute complications
such as heart failure, cardiogenic shock, and life threatening arrhyth-
mias, the current evidence suggests that its overall prognosis is good,
with a complete recovery in the vast majority of patients and a 1-year
recurrence rate around 5% [5,13–16]. More recent studies, however,
suggest a somewhat different picture, showing that SCM patients may
have high 1-year mortality rates from non-cardiovascular causes [17]
as well as high rates of re-hospitalization for atypical chest pain and
other cardiovascular causes [18]. The available information on the
long-termmorbidity andmortality of this condition, however, is limited
and mostly based on case series.under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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post-discharge prognosis of women diagnosed with SCM compared to
female controls with an ST-segment elevation myocardial infarction





Since the vast majority of SCM patients are female, to eliminate con-
founding by gender only female patients were included in this analysis.
SCM cases were identiﬁed through chart reviews of women hospital-
ized at the UMass Memorial Medical Center in Worcester, MA with an
ICD-9 code of 429.83 (takotsubo cardiomyopathy) as well as from
catheterization and echocardiography lab lists between January 1, 2002
and December 31, 2012. To be eligible, cases had to have a ﬁrst episode
of SCM and fulﬁll Mayo Clinic diagnostic criteria (transient wall motion
abnormality involving the left ventricular segments with or without
apical involvement; absence of obstructive coronary plaque or evidence
of plaque rupture or thrombosis at the coronary angiogram; new ST-
segment elevation and/or T wave inversion or modest troponin eleva-
tion) [19]. Consistent with these criteria, women with a history of head
trauma, intracranial bleeding, pheochromocytoma, myocarditis or
hypertrophic cardiomyopathy were excluded. Two trained physician
abstractors independently reviewed all SCM cases and agreement on
the diagnosis was reached in 100% of cases.
2.1.2. Controls
Controls were selected from a cohort of womenwith STEMI enrolled
in the Worcester Heart Attack Community Surveillance Study (WHAS).
Details about this study have been described elsewhere [20–22]. Brieﬂy,
this was a population-based study examining long-term trends in the
incidence and in-hospital and post-discharge case-fatality rates of
acute myocardial infarction among residents of central Massachusetts.
Individuals with a principal or secondary discharge diagnosis of
acute myocardial infarction (ICD-9 code 410), with the exclusion of
patients with peri-operative or trauma-associated myocardial in-
farction, were recruited from 16 teaching and community hospitals
in central Massachusetts between 1975 and 2009 (the number of
hospitals became smaller during the course of the study as a result
of hospital mergers and consolidations). A diagnosis of STEMI was
deﬁned according to standard diagnostic criteria [23]. The duration
of follow-up ranged from 2 to 8 years depending on the index period
of hospitalization.
For key predictors such as age we did not anticipate substantial con-
founding with case/control status, as SCM and STEMI both occur more
frequently in post-menopausal women. Thus, controls were randomly
sampled (rather than selected by individual matching) in a 2:1 ratio of
controls to cases among women enrolled in the WHAS between 2002
and 2009. Confounding was addressed by including in multivariable
models all baseline characteristics that were associated with the out-
comes under study [24–26].
2.2. Study outcome
The main study outcome was a composite of death from any cause
and cardiovascular readmissions. The date corresponding to the earliest
event was used in time-to-event analyses. Death status was ascertained
through a review of themedical record and through a systematic search
of the Death Master File from the Social Security Administration. In the
WHAS, cardiovascular readmissions were coded as an aggregate diag-
nosis, and deﬁned as any readmission for myocardial infarction, angina,
stroke, transient ischemic attack, coronary revascularization, cardiac ar-
rhythmia, or heart failure. Trained physician abstractors blinded to thestudy outcomeobtained information about cardiovascular readmissions
for cases and controls through reviews of each participant's medical
record.2.3. Confounders
The selection of possible confounding variables was based on the
published literature and on whether these variables were associated
with the study outcomes in univariate analyses. Information regarding
potential confounders such as age, race, marital status, coronary risk
factors (hypertension, cholesterol levels, diabetes, smoking status,
family history of coronary heart disease, body mass index), other
co-morbidities (history of angina, heart failure, stroke, cancer (any
cancer), liver disease and kidney disease/renal failure), andmedications
prescribed at the time of hospital discharge (e.g., aspirin, beta-blockers,
ACE inhibitors/angiotensin receptor blockers, warfarin, clopidogrel,
statins, calcium-channel blockers, nitroglycerin, diuretics) was collected
from the medical record by trained nurses and physician abstractors.
Since information about Killip class at admission was not collected in a
large number of cases and controls, systolic blood pressure at admission
was used as a proxy.
This study was approved by the Institutional Review Board at the
University of Massachusetts Medical School.3. Data analysis
t-Test (or non-parametric tests where appropriate for non-normally
distributed continuous variables) and chi square were used to compare
baseline characteristics of cases and controls. Survival curves were
generated by the Kaplan–Meier method and log-rank testing was used
to compare survival curves. Participants were censored at the date of
last contact or loss to follow-up. Risk of death and cardiovascular
readmissions (with the STEMI as the reference group) was estimated
fromCox proportional hazard regressionmodels adjusted for covariates
that were associated with the study outcomes in univariate analyses.
Results are presented as unadjusted and adjusted hazard ratios with
95% conﬁdence intervals; P-values b 0.05 were considered signiﬁcant.
All statistical analyses were performed using SAS/STAT® version 9.3,
SAS Institute, Cary, NC.4. Results
4.1. Baseline characteristics of cases and controls
Among 356women diagnosedwith SCM between January 2002 and
December 2012, we identiﬁed a cohort of 50 female patients with com-
plete angiographic and echocardiographic data with a ﬁrst episode of
SCM and who met Mayo Clinic diagnostic criteria. Clinical characteris-
tics at admission (showed in Table 1) were fairly similar between SCM
cases and STEMI controls (n = 100), except for age (mean, 65 years
in cases and 71 years in controls) and for a higher prevalence of hyper-
lipidemia and other coronary risk factor amongwomenwith STEMI. The
latter also tended to have a higher prevalence of non-cardiovascular co-
morbidities andwere alsomore likely to have a history of angina, stroke
and heart failure compared with women with SCM.While SCMwomen
apparently had a worse clinical presentation, as indicated by a lower
systolic blood pressure at admission and a worse ejection fraction,
they less frequently developed complications such as pulmonary
edema and hypotension during hospitalization. With the exception
of warfarin and diuretics, at discharge SCM women less frequently
received pharmacological treatments such as aspirin, beta-blockers,
lipid lowering agents and ACE inhibitors compared to women with
STEMI.
Table 1






Duration of follow-up in months
(mean (SD))
28.3 (31.4) 21.4 (26.4) 0.16
Demographics
Age (mean (SD)) 65.9 (14.3) 71.1 (14.9) b0.05
Race/ethnicity 0.24
White non-Hispanic 90.0 89.0
African American 0.0 3.0
Hispanic 4.0 4.0
Asian 0.0 2.0




Body mass index 0.10
Normal (b25) 57.1 38.8
Overweight (25–29) 16.7 30.6
Obese (30+) 26.2 30.6
Hyperlipidemia 42.0 61.0 b0.05
Family history of CHD 34.0 46.0 0.16
Hypertension 66.0 74.0 0.31
Diabetes 22.0 29.0 0.36
Current smoker 22.0 30.0 0.29
Ex-smoker 40.0 26.0 0.08
Never smoker 32.0 39.0 0.40
Medical history
Angina 2.0 7.0 0.16
Heart failure 10.0 19.0 0.14
Stroke 4.0 12.0 0.09
Cancer (any cancer) 12.0 16.0 0.51
Liver disease 0.0 2.0 0.20
Kidney disease 6.0 20.0 b0.05
Clinical characteristics
Admission SBP (mean (SD)) 120.8 (29.4) 137.3 (27.6) b0.01
Admission heart rate (mean (SD)) 86.8 (20.1) 81.2 (24.5) 0.20
ST elevation at admission ECG 48.0 97.0 b0.001
T wave inversion at admission ECG 24.0 25.0 0.89
Left ventricular ejection fraction (admission
echocardiogram, mean (SD))
31.8 (8.7) 46.6 (12.3) b0.001
Peak CPK (SI) (mean (SD)) 320 (449.8) 607 (961.2) b0.05
Peak troponin I (SI) (mean (SD)) 6.1 (8.8) 12.9 (27.3) b0.05
Length of stay in days (mean (SD)) 6.42 (10.5) 6.11 (5.8) 0.85
Complications during hospitalization
Heart failure or pulmonary edema 14.0 36.0 b0.05
Hypotension 32.0 56.0 b0.01
Intra-aortic balloon pump placement 4.0 3.0 0.75
CABG 0 4.0 0.07
PCI 0 63.0 b0.001
Medications at discharge
β-Blocker 70.0 86.0 b0.05
ACE inhibitor/angiotensin receptor blocker 58.0 67.0 0.28
Aspirin 66.0 97.0 b0.001
Statin 50.0 91.0 b0.001
Warfarin 14.0 11.0 0.60
Clopidogrel 10.0 80.0 b0.001
Calcium channel blocker 10.0 0.0 b0.01
Nitroglycerin 16.0 58.0 b0.001
Diuretics 20.0 0.0 b0.001
Fish oil 24.0 69.0 b0.001
SCM = stress cardiomyopathy.
STEMI = ST elevation MI.
CHD = coronary heart disease.
SBP = systolic blood pressure.
CABG = coronary artery bypass grafting.
PCI = percutaneous coronary intervention.
a Numbers are % unless otherwise indicated.
b t-Test or chi square.
25E. Salmoirago-Blotcher et al. / IJC Metabolic & Endocrine 4 (2014) 23–274.2. Composite outcome
Over an average post-discharge follow-up period of 24 months
(range, 0 to 120) the incidence rate of the composite outcome of
all-cause mortality and cardiovascular readmissions (Table 2) was
140/1000 person-years among SCM and 347/1000 person-years
among STEMI participants (P b 0.001). Kaplan–Meier survival curves
for STEMI and SCM women are shown in Fig. 1.
Compared with STEMI, SCM women had a 53% lower unadjusted
risk of cardiovascular readmissions and death vs. STEMI controls
(HR: 0.47; 95% CI: 0.27, 0.82; P b 0.01). After adjustment for age and
additional variables that were associated with the composite outcome
including comorbidities, smoking status, presence of ST-segment eleva-
tion at admission, heart rate at admission and prescription of aspirin
and statins at discharge, SCM women had a 36% lower risk of the com-
posite outcome compared with STEMI women and the between-group
difference was no longer statistically signiﬁcant (HR: 0.64; 95%
CI: 0.30, 1.33, P= 0.26).
4.3. Individual outcomes
With regard to each individual outcome that comprised our compos-
ite outcome, incidence rates of all-cause death was 271/1000 person-
years among cases and 376/1000 person-years among controls
(P b 0.001). After multi-variable adjustment, the risk of all-cause
mortality was signiﬁcantly lower among SCM cases vs. STEMI controls
(HR= 0.10; CI: 0.02, 0.51; P b 0.01). As for cardiovascular readmissions,
incidence rates among SCM cases and STEMI controls were, respectively,
85/1000 person-years and 134/1000 person-years (P= 0.35). Reasons
for cardiovascular readmissions among SCM cases included heart failure
(3), non-ST segment elevation myocardial infarction (3), chest pain
(2), atrial ﬁbrillation (2) and recurrence of SCM (3). After adjustment
for confounders, the risk of cardiovascular readmissions was similar
between the 2 groups (HR: 0.93; 95% CI: 0.38, 2.28; P= 0.26).
5. Discussion
In this retrospective cohort study women with SCM had an overall
better prognosis after hospital discharge compared to women with
STEMI. Differences in overall prognosis, however, were markedly re-
duced upon adjustment for confounders. Furthermore, while all-cause
mortality rates were signiﬁcantly lower among SCM cases than among
STEMI controls, the incidence rates of cardiovascular readmissions
among SCM female patients were high and did not signiﬁcantly differ
from those of women with STEMI.
There is general consensus in the literature that the short-termprog-
nosis of SCM is good. A systematic review of 28 case series has shown
that despite a high prevalence of serious acute complications such as
heart failure, cardiogenic shock, and life threatening arrhythmias, the
vast majority of patients (95%) recover completely and the in-hospital
mortality is about 2% [5]. Recurrence rates between 3% and 5% have
been reported at one year after discharge [5,13–17] and fairly similar
recurrence rates (11% over 4 years) following the initial diagnosis
have been found in a large single-center case series [27]. More recent
studies, however, have indicated that SCM may not be an entirely
benign condition. A large case series of 136 cases (96%women) reported
mortality rates for SCM of 13% over 4 years of follow-up [17]. Data
from an Italian registry of 116 consecutive patients indicated that re-
hospitalizations for atypical chest pain and other cardiovascular causes
in these patients may reach 25% over a 2 year follow-up period [18].
Although the incidence rates found in our study cannot be compared
with previously publishedﬁndings because these former studies usually
estimated the overall risk of mortality or re-hospitalization, the risk of
hospital readmissions for cardiac reasons in our SCM population (26%
over an average follow-up of 2 years) was remarkably similar to the








Composite outcome 16 (32%) 61 (61%) b0.001
Incidence rates 140/1000 person-years 347/1000 person-years b0.001
Unadjusted HR 0.47 (0.27, 0.82) Reference b0.01
Age-adjusted HR 0.57 (0.32, 0.99) Reference b0.05
Multivariate HRb 0.64 (0.30, 1.33) Reference 0.26
Cardiovascular readmissionsb 13 (26%) 35 (35%) 0.26
Incidence rates 85/1000 person-years 134/1000 person-years 0.35
Unadjusted HR 0.72 (0.38, 1.38) Reference 0.32
Age-adjusted HR 0.79 (0.41, 1.52) Reference 0.48
Multivariate HRb 0.93 (0.38, 2.28) Reference 0.88
All-cause mortality 4 (8%) 44 (44%) b0.001
Incidence rates 271/1000 person-years 376/1000 person-years b0.001
Unadjusted HR 0.18 (0.06, 0.49) Reference b0.001
Age-adjusted HR 0.20 (0.07, 0.57) Reference b0.01
Multivariate HRb 0.10 (0.02, 0.51) Reference b0.01
SCM = stress cardiomyopathy.
STEMI = ST elevation MI.
a Multivariate models adjusted for variables associated with the outcomes in univariate analyses: age, history of diabetes, history of heart failure, history of kidney disease, smoking, ST
elevation at admission, heart rate at admission, and prescription of aspirin and statin at discharge.
b Reasons for cardiovascular readmissions among SCM women included heart failure (3), non-STEMI (3) chest pain (2) atrial ﬁbrillation (2) and recurrence of SCM (3).
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ated with this condition. Likewise, the risk of all-cause mortality post-
discharge detected in our study (8% over an average follow-up duration
of 2 years) was similar to the one reported in a large single-center case
series (13% over a follow-up of about 3 years) [17].
Previous studies documenting the post-discharge prognosis of SCM,
however, had several methodological limitations that the present study
has attempted to overcome. Prior studies were typically case series,
lacked a comparison group, and/or were unable to account for the
confounding effect of several important demographic and/or clinical
variables on post-discharge survival and/or risk of cardiovascular
outcomes.
5.1. Study strengths and limitations
This study has several important strengths. The current knowledge
about the long-term prognosis of this interesting condition is based onFig. 1. Kaplan–Meier curves for the composite outcome of post-dischacase series and registries; in this study, we attempted to overcome
this limitation by including a comparison group of women with
STEMI, and to account for confounding byusingmultivariablemodeling.
Second, physician abstractors validated all cardiovascular events among
both cases and controls; and lastly, this is, to the best of our knowledge,
the ﬁrst study focusing on a female population.
This study also has some limitations. First, only womenwere includ-
ed in this analysis and thus our results do not apply to a male popula-
tion. However, while SCM affects both sexes, it is outstandingly more
common in women. The characteristics and the prognosis of SCM in
males likely differ from female patients and need to be studied in a
much larger study with the statistical power to detect gender differ-
ences. Second, although we considered several possible confounders,
information about education, socio-economic status and behavioral fac-
tors (i.e. diet and physical activity) that may affect the post-discharge
prognosis of this condition was not available and thus we were not
able to adjust for these important confounding variables. Third, despiterge death and cardiovascular readmissions in cases and controls.
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SCM cases might have produced selection bias. Since to fulﬁll Mayo
Clinic diagnostic criteria a coronary angiogram is required, women
who are too sick to undergo an angiogram or die before an angiogram
is performed are typically excluded. The consequence is an underesti-
mation of the risk of mortality among SCM women, and consequently
the difference in mortality between SCM and STEMI women observed
in this study might have been overestimated. All studies using Mayo
Clinic criteria, however, have been subject to this type of bias, which
should be taken into account in future studies. An additional reason
that might explain the low all-cause mortality rates among our cohort
of SCMwomen is that we used the original 2004Mayo Clinic diagnostic
criteria [19] calling for the exclusion of subjects developing SCM in asso-
ciation with neurologic events such as sub-arachnoid hemorrhage and
intracranial bleeding.
Finally, since in theWHAS cardiovascular re-admissions were coded
as an aggregate diagnosis (as any readmission for myocardial infarction,
angina, stroke, transient ischemic attack, coronary revascularization,
cardiac arrhythmia, or heart failure), information about the diagnosis
for each cardiovascular readmissionwas not available for STEMIwomen.
In conclusion, while the in-hospital prognosis of SCM among female
patients is good and usually associated with a complete recovery in a
large majority of cases, the prognosis of this condition after discharge
appears to be less favorable. Women with SCM had a high absolute
risk of cardiovascular readmissions, and confounding explained most
of the difference between SCM and STEMI women observed in unad-
justed models. Since the high rates of cardiovascular readmissions
observed among SCM women may result in signiﬁcant costs, large
epidemiological studies are warranted to deepen our knowledge of
the characteristics and the predisposing factors for the development of
this condition in order to develop adequate preventive strategies.
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